Skip to main content
Apellis Pharmaceuticals, Inc. logo

Apellis Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · APLS ISIN · US03753U1060 LEI · 254900HS0ZFRXXSB9D42 US Manufacturing
Open in API
Filings indexed 1,129 across all filing types
Latest filing 2024-01-16 Regulatory Filings
Country US United States of America
Listing US APLS

About Apellis Pharmaceuticals, Inc.

https://apellis.com/

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing therapies for a broad range of debilitating diseases by targeting the complement cascade. The company's scientific approach is centered on controlling C3, a central protein in this part of the immune system, to treat conditions driven by its overactivation. Apellis's development efforts are concentrated in the areas of ophthalmology, hematology, and nephrology. Its portfolio of approved medicines includes SYFOVRE® (pegcetacoplan injection) for the treatment of geographic atrophy (GA) and EMPAVELI® (pegcetacoplan) for other serious, complement-driven diseases.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings
2024-01-16 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 8, 2024, reporting preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2023. It includes a press release as Exhibit 99.1 announcing these preliminary results. The document explicitly states that the financial figures are preliminary, unaudited, and represent management's estimates, and that the independent auditor has not reviewed or audited these figures. The document is short (3984 characters) and primarily serves to announce the preliminary financial results via a press release rather than providing a full detailed financial report. This fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly or periodical financial results with key highlights only. It is not a full Interim/Quarterly Report (IR) because it lacks substantive financial statements or detailed analysis. Therefore, the correct classification is Earnings Release (ER).
2024-01-08 English
PRIMARY DOCUMENT
Director's Dealing
2024-01-05 English
Regulatory Filings 2024
Regulatory Filings
2024-01-04 English
PRIMARY DOCUMENT
Director's Dealing
2024-01-02 English
PRIMARY DOCUMENT
Director's Dealing
2024-01-02 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.